Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...gy/drugbank/group
| |
http://linked.open...ugbank/indication
| - Used as adjunctive therapy for the treatment of peptic ulcer. Also used to treat nausea and vomiting due to motion sickness. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| - Methylscopolamine bromide (en)
|
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Methscopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center). It does so by acting as a muscarinic antagonist. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open.../drugbank/synonym
| - Pamine (en)
- Hyoscine Methobromide (en)
- Scopolamine Methobromide (en)
- (−)-scopolamine methobromide (en)
- (−)-scopolamine methyl bromide (en)
- Hyoscine methyl bromide (en)
- Methscopolamine bromide (en)
- N-methylhyoscine bromide (en)
- N-methylscopolammonium bromide (en)
- Scopolamine methyl bromide (en)
|
http://linked.open...drugbank/toxicity
| - Symptoms of a methscopolamine overdose include headache, nausea, vomiting, dry mouth, difficulty swallowing, blurred vision, dilated pupils, hot, dry skin, dizziness; drowsiness, confusion, anxiety, seizures, weak pulse, and an irregular heartbeat. In addition, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis. (en)
|
http://linked.open.../drugbank/mixture
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Poorly and unreliably absorbed, total absorption is 10-25%. (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...aco2-Permeability
| |
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |